Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 16Uterine Cervical Neoplasms 5Stomach Neoplasms 5Lung Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Hepatocellular 5Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Prostatic Neoplasms 4Ovarian Neoplasms 4Oropharyngeal Neoplasms 4Esophageal Neoplasms 4Cholangiocarcinoma 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Neuroendocrine Tumors 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Anus Neoplasms 3Testicular Neoplasms 2Solid Tumor 2Pheochromocytoma 2Paraganglioma 2Pancreatic Neoplasms 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Leukemia, Myeloid, Acute 2Laryngeal Neoplasms 2

Interventions

Carboplatin 47Etoposide 46durvalumab 28atezolizumab 28Cisplatin 21Topotecan 19pembrolizumab 15PM 01183 15Nivolumab 12Specimen Handling 11anlotinib 9Radiotherapy 9Paclitaxel 9Drug Therapy 9Temozolomide 8Magnetic Resonance Spectroscopy 8AMG 757 8Radiosurgery 7Platinum 7Irinotecan 7toripalimab 6olaparib 6Biopsy 6Ipilimumab 5Injections 5Docetaxel 5Bevacizumab 5trilaciclib 4tremelimumab 4tislelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Fluorodeoxyglucose F18 × 1 year × Clear all
NCT06503146 2026-05-19

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
320 enrolled
CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡